ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 332

Blockade of CTGF Restores Aberrant Ostoclastgenesis in Collagen Induced Arthritis (CIA) Mice Through Inhibition of Th-17 Differentiation

Kazuhisa Nozawa1, Maki Fujishiro2, Ayako Yamaguchi1, Mikiko Kawasaki2, Shouzou Ichinose2, Mitsuaki Yanagida2, Kazuhisa Iwabuchi2, Keigo Ikeda3, Shinji Morimoto4, Megumi Morioka5, Yoshinari Takasaki6 and Iwao Sekigawa3, 1Rheumatology, Juntendo University School of Medicine, Tokyo, Japan, 2Institute for Environment and Gender Specific Medicine, Juntendo University Graduate School of Medicine, Chiba, Japan, 3Internal Medicine 2, Juntendo University Urayasu Hospital, Tomioka, Urayasu, Chiba, Japan, 4Juntendo University Urayasu Hospital, Tokyo, Japan, 5Nihon Nosan Corporation, Nihon Nosan Corporation, Kanagawa, Japan, 6Internal Medicine and Rheumatology,, Juntendo University School of Medicine, Tokyo, Japan

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: Animal models, inflammatory arthritis, interleukins (IL), osteoclastogenesis and rheumatoid arthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Rheumatoid Arthritis: Animal Models

Session Type: Abstract Submissions (ACR)

Background/Purpose: Our previous study demonstrated changes in the profiles of serum protein biomarkers in infliximab-treated rheumatoid arthritis (RA) patients using a novel approach to proteomic research. Several proteins exhibited vast changes in expression after infliximab treatment, and we have reported connective tissue growth factor (CTGF) appeared to be a potent strong biomarker in infliximab-treated RA patients. Furthermore, we also found that CTGF was upregulated in both serum level and tissue expression of patients with RA, and that CTGF was related to disease progression of RA through abnormal activation of osteoclasts in vitro. To extend our research project, this study was conducted to clarify roles of CTGF for RA pathogenesis. To investigate more precise roles of CTGF for RA pathogenesis, we analyzed effects of blockade against CTGF pathway on the progression of arthritis in collagen induced arthritis (CIA) mouse.

Methods: CIA was introduced in DBA/1J mice by immunization in combination with typeIIcollagen and complete Freund’s adjuvant (CFA). The efficacy and mechanisms for prevention of the arthritis were evaluated in the mice treated with or without neutralizing anti-CTGF monoclonal antibody (mAb).

Results: The blockade of CTGF by anti-CTGF mAb treatment significantly ameliorated the arthritis compared to the non-treated controls. Moreover, serum levels of C reactive protein (CRP) and matrix metalloproteinase (MMP)-3 reduced in the CTGF-treated mice. The blockade of CTGF decreased interleukin (IL)-17 and IL-21 production from purified CD4+ T lymphocytes. Although gene expression of retinoic-acid-receptor-related orphan receptors gamma t (RORgt) was not suppressed by anti-CTGF mAb treatment, those of interferon regulatory factor-4 (IRF-4) and IkappaBzeta, which are other important molecules for Th-17 differentiation, were suppressed. In addition, the blockade of CTGF inhibited pathological T lymphocytes proliferation against typeIIcollagen restimulation extra vivo. Moreover, aberrant sRANKL/MCSF-induced osteoclastgenesis of CD14+ progenitor cells in CIA was restored by anti-CTGF mAb treatment.

Conclusion: The present study demonstrated that the blockade of CTGF significantly prevented a progression of arthritis in CIA mice. The administration of anti-CTGF mAb had suppressive effects on aberrant pathological T cells proliferation and Th17 differentiation in CIA mice. In addition, the blockade of CTGF pathway might restore aberrant ostoclastgenesis of CIA through direct effect to CD14+ osteoclastic progenitor cells and indirect effects for Th-17 differentiation. CTGF may become a new target molecule for treatment of RA.


Disclosure:

K. Nozawa,
None;

M. Fujishiro,
None;

A. Yamaguchi,
None;

M. Kawasaki,
None;

S. Ichinose,
None;

M. Yanagida,
None;

K. Iwabuchi,
None;

K. Ikeda,
None;

S. Morimoto,
None;

M. Morioka,
None;

Y. Takasaki,
None;

I. Sekigawa,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/blockade-of-ctgf-restores-aberrant-ostoclastgenesis-in-collagen-induced-arthritis-cia-mice-through-inhibition-of-th-17-differentiation/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology